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Background: Patients undergoing therapeutic plasma exchange (TPE) may present
with risks for hemorrhage or thrombosis. Use of replacement fluids devoid of coag-
ulation factors will decrease factor levels and platelet levels. There are no estab-
lished guidelines for hemostasis management in these situations.
Materials and methods: A survey to evaluate current hemostasis management
practice during TPE was conducted using online survey software. One response
per institution was analyzed based on a hierarchical algorithm, excluding mem-
brane filtration users, resulting in a maximum of 107 respondents. Descriptive anal-
ysis was performed with results reported as the number and frequency (%) of
respondents to each question.
Results: Apheresis Medicine physicians, alone (59.4%) or jointly with the request-
ing provider (29.2%), choose the replacement fluid. Based on a theoretical patient
case receiving five TPEs approximately every other day, the percent of respondents
who would use albumin with or without normal saline was 94.7% with no history
of a bleeding or clotting disorder, 1.1% with active bleeding, and 8.8% with hypofi-
brinogenemia (<100 mg/dL) due to recent TPE. More respondents would use albu-
min with or without normal saline for replacement fluid when a minor invasive
procedure (49.5%) vs a major surgery (8.9%) was performed 1 day before TPE.
Replacement fluid selection varied among respondents for several other clinical
conditions. The most frequent use for cryoprecipitate by respondents (14.3%) was
hypofibrinogenemia.
Conclusions: These survey results demonstrate wide interinstitutional variation in
replacement fluid selection to manage hemostasis in patients undergoing TPE. Fur-
ther studies are needed to guide optimal hemostasis management with TPE.
KEYWORDS
anticoagulation, apheresis, bleeding, coagulation, plasmapheresis
1 | INTRODUCTION
Apheresis is a procedure in which blood of the patient or
donor is passed through a medical device which separates one
or more components of blood and returns the remainder with
or without extracorporeal treatment or replacement of the sep-
arated component.1 Therapeutic apheresis has become a
widely used treatment or treatment alternative for many dis-
eases or disease conditions, among which therapeutic plasma
exchange (TPE) is the procedure performed most commonly
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in clinical practice.1,2 TPE is a therapeutic apheresis procedure
in which the plasma is removed and replaced with a solution
such as colloid solution (eg, albumin and/or plasma) or a com-
bination of crystalloid/colloid solution. TPE procedures per-
formed with centrifugation based devices may remove
pathologic substances (eg, toxins, autoantibodies, and parapro-
teins) as well as normal plasma constituents (eg, coagulation
factors and natural anticoagulants).3–7 Circulating medications,
such as anticoagulants, may also be removed.8–11 Because of
the removal of coagulation factors and anticoagulants, it is a
challenge in clinical apheresis medicine to maintain patients in
a safe hemostasis status, which is further compounded in
patients with an underlying risk for or ongoing hemorrhage or
thrombosis.
Currently, there are no consensuses or national guide-
lines regarding hemostasis management in patients undergo-
ing TPE treatments. To understand current practice, the
Coagulation Subcommittee of the American Society for
Apheresis (ASFA) Applications Committee conducted a sur-
vey regarding hemostasis management and TPE. This manu-
script contains management practice data on the replacement
fluid choice for patients undergoing TPE, while the labora-
tory testing practices are described in the associated article
by Zantek et al.12 The aim of this study is to describe and
characterize the current practice of replacement fluid selec-
tion for patients undergoing TPE.
2 | METHOD
A survey was developed by the members of the Coagulation
Subcommittee of the ASFA Applications Committee to eval-
uate management of hemostasis in patients undergoing TPE.
The development, implementation, and analysis of the sur-
vey is described in the associated article by Zantek et al.12
The data analyzed here represents the second portion of the
survey. Because of decreasing numbers of responses through
the progression of the survey, only those respondents that
answered question 27 of 37 questions “What method of cell
separation do you typically use for TPE” are included in the
data set analyzed here. From the initial 167 responses, a total
of 107 were included in these analyses. The reasons that
60 responses were excluded are as follows: 16 were dupli-
cate responses, 24 were more than one response received
from an institution, 15 did not answer question 27 of
37 (method of apheresis question), and 5 indicated they use
membrane filtration or centrifugation and/or membrane fil-
tration techniques.
3 | RESULTS
Demographic information is provided in Table 1. The
respondents were mostly comprised of physicians (including
physicians-in-training) and nurses and the procedures are
mostly performed or overseen in the departments of Pathol-
ogy and Hematology. Respondents who perform TPE on
pediatric patients define a pediatric patient based on age
(78.2%) or weight (22.8%). The most common age used by
respondents to define a pediatric patient was 18 years
(59.4%). Weight-based definitions were varied and ranged
from 5 to 50 kg. The choice of replacement fluid to use for
TPE procedures was made by the Apheresis Medicine physi-
cian (59.4%), jointly by the Apheresis Medicine physician
and requesting provider (29.3%), the requesting provider
(8.5%), and other (2.8%).
3.1 | Routine practice at a responding center
To understand routine practice at a center, respondents were
asked how they manage a patient who presents for a series
of five TPE approximately every other day. The most com-
mon procedural parameters were a 1.0 plasma volume
(63.2%) and use of anticoagulant citrate dextrose A for extra-
corporeal anticoagulation (97.1%).12 The choice of replace-
ment fluid was albumin, albumin and normal saline, plasma,
albumin and plasma, and other by 47.7%, 12.2%, 3.7%,
2.8%, and 33.6% of respondents, respectively. Comments
were provided by all 36 respondents who selected other for
replacement fluid; no comments were entered by respon-
dents who selected a specific replacement fluid. The com-
ments from 27 of the 36 respondents included some form of
the word “depend.” Interpreting the 36 text comments, the
choice of replacement fluid would depend on the diagnosis
(80.6%), laboratory values (11.1%), and both diagnosis and
laboratory values (8.3%).
3.2 | TPE with a potential bleeding risk
When a patient presents for a series of five approximately
every other day TPE with an associated potential bleeding
risk, wide variation in the selection of replacement fluid was
observed (Table 2). Similar to the case scenario used to deci-
pher the respondent's routine practice, 27 respondents
entered comments, many noting the replacement fluid choice
would depend on the condition treated and other issues, such
as results of laboratory studies and the specific patient clini-
cal scenario. No respondent selected the same replacement
fluids for all of the situations presented. However, 2 (2.1%)
respondents only selected replacement fluids containing
some or all plasma and 3 (3.2%) respondents only selected
replacement fluids containing some or all plasma or cryopre-
cipitate or would chose to delay the procedure for the scenar-
ios they provided a response.
3.3 | Invasive procedures
The replacement fluid selection was associated with the tim-
ing of minor invasive procedures and major surgery as
shown in Tables 3 and 4. There was a trend after either a
minor or major procedure to switch from a replacement fluid
2 ZANTEK ET AL.
ZANTEK ET AL. 605
TABLE 1 Demographic information of survey respondents and apheresis programs
Question (number of respondents)a Number (%)b
Position at institutionb (n = 107)c
Physician (including physician in training-resident/fellow) 67 (62.6)
Director of apheresis service 25 (37.3)
Member of physician teaching staff 19 (28.4)
Residency/fellowship program director 4 (5.0)
Other 6 (9.0)
Nurse 27 (25.2)
Director of apheresis service 2 (7.4)
Member of nonphysician teaching staff 1 (3.7)
Other 2 (7.4)
Director of apheresis (did not indicate physician or nurse) 10 (9.3)
Member of nonphysician teaching staff 1 (10.0)
Other 3 (2.8)
Type of institution (n = 107)
Academic medical center 74 (69.2)
Blood collection facility 13 (12.2)
Non-academic medical center 6 (5.6)
Contract provider of apheresis services 5 (4.7)
Outpatient facility that performs apheresis 1 (0.9)
Other 8 (7.5)

















Performed by outside source but overseen by pathology 7 (6.6)
Performed by outside source but overseen by neurology 3 (2.8)
Performed by outside source but overseen by hematology 2 (1.9)
Performed by outside source but overseen by nephrology 2 (1.9)
Performed by outside source but overseen by rheumatology 1 (0.9)
Performed by outside source but overseen by medicine 1 (0.9)
Other 22 (20.8)
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containing coagulation factors to albumin with or without
normal saline. Some respondents entered free text comments
to describe their practice, which indicated the choice of
replacement fluid would depend on screening coagulation
laboratory test results, such as the prothrombin time (PT),
international normalized ratio (INR), partial thromboplastin
time (PTT), and fibrinogen, or liver function test results.
3.4 | Kidney biopsy
The replacement fluid choice after kidney biopsy is shown
in Supporting Information Table S1. The majority of respon-
dents (65.5%) indicated their routine practice for use of
plasma in the replacement fluid after kidney biopsy
depended on the number of days, hours, or procedure num-
bers since the biopsy, while 19.0% only use plasma when
there is bleeding. When plasma is used up to specific days
postbiopsy, 27 respondents indicated the number of days
postbiopsy that plasma would be used is as follows (n, %):
1 day (5, 18.5%), 2 days (9, 33.3%), 3 days (4, 14.8%),
3-5 days (1, 3.7%), 5 days (3, 11.1%), 14 days
(1, 3.7%),15 days (1, 3.7%), and other (3, 11.1%). When
plasma is used up to specific hours postbiopsy, four respon-
dents provided a comment: one indicated plasma would be
used up to 24-48 hours, one indicated up to 48 hours, and
two indicated up to 72 hours. When plasma is used up to a
specific number of procedures, eight respondents provided a
comment: two indicated up to three TPE, one indicated up to
seven TPE, and five provided a comment that did not give a
specific procedure number. Additionally, a few respondents
stated the amount of plasma they would use, which ranged
from 30% to 100% of plasma replacement volume, and one
respondent indicated a specific volume of 4 units of plasma
would be used as part of the replacement fluid.
3.5 | Antiplatelet and anticoagulant therapy
Antiplatelet therapy use is common among the general popu-
lation and may be used by patients undergoing TPE. The
replacement fluid selection in the setting of an inherited or
acquired platelet disorder is described in Table 2.The survey
showed 8 out of 81 (9.9%) respondents would stop ongoing
TABLE 1 (Continued)
Question (number of respondents)a Number (%)b
I am not a physician 19 (20.0)
Perform TPE procedures on children (n = 107)
Yes, adults and children 69 (64.5)
No 32 (29.9)
Yes, children only 6 (5.6)
a For some questions respondents were requested to check all that apply and the total number of responses is greater than the number of respondents.
b For questions that permitted more than one response, the percent is based on the number of respondents to the question.
c Total number of responses = 167.
d Total number of responses = 173.
TABLE 2 Replacement fluid selection for therapeutic plasma exchange (TPE) in patients with an associated clinical situation and scheduled to receive five
















No history of a bleeding or clotting disorder (n = 94) 71 (75.5) 18 (19.1) 4 (4.3) 0 (0.0) 1 (1.1) 0 (0.0)
Active bleeding (n = 94) 0 (0.0) 1 (1.1) 35 (37.2) 0 (0.0) 41 (43.6) 17 (18.1)
Bleeding disorder due to coagulation factor deficiency (eg,
hemophilia A, B, or C; von Willebrand disease) (n = 90)
9 (10.0) 0 (0.0) 35 (38.9) 4 (4.4) 35 (38.9) 7 (7.8)
Platelet disorder (inherited or acquired) (n = 91) 39 (42.9) 11 (12.1) 24 (26.4) 2 (2.2) 12 (13.2) 3 (3.3)
Hypofibrinogenemia (<100 mg/dL) due to recent TPE (n = 91) 8 (8.8) 0 (0.0) 45 (49.5) 13 (14.3) 20 (22.0) 5 (5.5)
Therapeutic on continuous IV unfractionated heparin (n = 89) 31 (34.8) 9 (10.1) 28 (31.5) 2 (2.3) 13 (14.6) 6 (6.7)
Supratherapeutic on continuous IV unfractionated heparin
(n = 88)
19 (21.6) 7 (8.0) 24 (27.3) 2 (2.3) 22 (25.0) 14 (15.9)
Therapeutic on low molecular weight heparin (eg, enoxaparin)
(n = 87)
45 (51.7) 12 (13.8) 22 (25.3) 3 (3.5) 5 (5.8) 0 (0.0)
Supratherapeutic on low molecular weight heparin (eg,
enoxaparin) (n = 85)
28 (32.9) 7 (8.2) 24 (28.2) 2 (2.4) 15 (17.7) 9 (10.6)
Therapeutic (INR 2.5) on warfarin (n = 87) 39 (44.8) 9 (10.3) 31 (35.6) 1 (1.2) 6 (6.9) 1 (1.2)
Supratherapeutic (INR 4.0) on warfarin (n = 85) 13 (15.3) 4 (4.7) 39 (45.9) 2 (2.4) 16 (18.8) 11 (12.9)
Liver disease with a mildly elevated INR (1.5-2.0) (n = 87) 29 (33.3) 4 (4.6) 43 (49.4) 1 (1.2) 10 (11.5) 0 (0.0)
Abbreviations: CRYO, cryoprecipitate; INR, international normalized ratio; n, number of respondents.
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aspirin therapy, an inhibitor of prostaglandin cyclooxygenase-1,
during a series of TPE, while 13 out of 80 (16.3%) respon-
dents would stop clopidogrel, an inhibitor of the P2Y12 class
of the adenosine diphosphate receptors on platelets. When the
patient is on both aspirin and clopidogrel (n = 79 respon-
dents), 9 (11.4%) respondents indicated both medications
would be stopped, while 3 (3.9%) would stop aspirin only,
and 7 (8.9%) would stop clopidogrel only.
Anticoagulants are frequently encountered in patients
undergoing TPE. See Table 2 for TPE replacement fluid
choices in the settings of unfractionated heparin, low molec-
ular weight heparin, and warfarin. Since 2010, there have
been a number of new anticoagulants approved by the FDA.
Respondents indicated they have performed TPE on patients
receiving these therapies: 20 out of 76 (26.3%) respondents
for oral direct factor Xa inhibitor (eg, rivaroxaban, apixaban,
edoxaban, and betrixaban); 16 out of 73 (21.9%) respondents
for oral direct thrombin inhibitor (eg, dabigatran); and
20 out of 72 (27.8%) respondents for intravenous direct
thrombin inhibitor (eg, argatroban, bivalirudin, and lepiru-
din). Respondents reported encountering patients on these
medications in the context of left ventricular assist device
(LVAD), extracorporeal membrane oxygenation (ECMO),
heparin induced thrombocytopenia (HIT), trauma, transplant
rejection, Blalock-Taussig shunt, and antiphospholipid anti-
body syndrome (APAS). Many respondents entered com-
ments regarding management during TPE in patients on
anti-Xa or direct thrombin inhibitors. Some respondents
stated a concern for thrombosis in patients on these medica-
tions outweighed concerns of bleeding, so that they would
not use a reversal agent or hold the procedure for 24 hours
after the last dose. Replacement fluid selection varied from
no change in practice to including some or all plasma. Some
respondents indicated they would hold the medications while
others would not.
4 | DISCUSSION
The selection of replacement fluid is a critical management
decision for patients undergoing TPE using centrifugation
based apheresis instruments. Based on available evidence,
the ASFA guidelines for therapeutic apheresis suggest
replacement fluids, but additional situational conditions may
influence this choice.1 A survey was conducted to assess the
current practice and the variation among apheresis providers.
To quote the respondents, the choice of replacement
fluid “depends” on several factors including the diagnosis
treated, laboratory studies, and other conditions present.
Respondents were asked to describe how they would man-
age a case patient that is undergoing a series of five TPE
approximately every other day. Our intent was to not bias
the choice of replacement fluid by giving a specific indica-
tion for the TPE; however, this likely resulted in respondents
considering very different patient scenarios. When more
clarity was given regarding the patient, that is, that the
patient had no history of a bleeding or clotting disorders,
94.7% of respondents would use albumin with or without
normal saline. The remaining five respondents would use
some or all plasma or delay the procedure for all of the clini-
cal situations for which they provided a response. In retro-
spect it may have been ideal to include two specific cases
where the replacement fluid choice suggested by the ASFA
TABLE 3 Timing of minor invasive procedure and replacement fluid used for therapeutic plasma exchange
In the morning of
TPE n (%) (n = 91)
1 day before TPE
n (%) (n = 91)
2 days before TPE
n (%) (n = 91)
2 days before TPE
with bleeding n (%) (n = 90)
Albumin 16 (17.6) 34 (37.4) 52 (57.1) 1 (1.1)
Albumin and NS 7 (7.7) 11 (12.1) 17 (18.7) 3 (3.3)
Albumin and plasma 41 (45.0) 38 (41.8) 16 (17.6) 49 (54.4)
Albumin and CRYO 1 (1.1) 0 (0) 1 (1.1) 0 (0)
Plasma 10 (11.0) 5 (5.5) 5 (5.5) 26 (28.9)
Delay procedure 16 (17.6) 3 (3.3) 0 (0) 11 (12.2)
Abbreviations: CRYO, cryoprecipitate; n, number of respondents; NS, normal saline; TPE, therapeutic plasma exchange.
TABLE 4 Timing of major surgery and replacement fluid used for therapeutic plasma exchange
2 days after
TPE n (%) (n = 90)
1 day after TPE
n (%) (n = 91)
1 day before TPE
n (%) (n = 90)
3 days before TPE
n (%) (n = 90)
1 week before TPE
n (%) (n = 90)
Albumin 35 (38.9) 10 (11.0) 5 (5.6) 24 (26.7) 53 (58.9)
Albumin and NS 11 (12.2) 7 (7.7) 3 (3.3) 12 (13.3) 16 (17.8)
Albumin and plasma 31 (34.4) 44 (48.4) 42 (46.7) 36 (40.0) 17 (18.9)
Albumin and CRYO 1 (1.1) 1 (1.1) 1 (1.1) 0 (0) 0 (0)
Plasma 11 (12.2) 24 (26.4) 31 (34.4) 16 (17.8) 2 (2.2)
Delay procedure 1 (1.1) 5 (5.5) 8 (8.9) 2 (2.2) 2 (2.2)
Abbreviations: CRYO, cryoprecipitate; n, number of respondents; NS, normal saline; TPE, therapeutic plasma exchange.
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guidelines is suggested to be albumin (eg, myasthenia
gravis) and plasma (eg, thrombotic thrombocytopenic pur-
pura).1 The ASFA recommendations of the Choosing Wisely
initiative of the ABIM Foundation recommends “Do not
routinely use plasma as replacement fluid for therapeutic
plasma exchange unless there is a clear indication to replete
a plasma component”.13
Cryoprecipitate was used by a small number of respon-
dents. The most frequent use was for fibrinogen replacement
in patients with hypofibrinogenemia because of recent TPE.
Small numbers of respondents (1 to 4) would use cryopreci-
pitate in other situations. In patients with a coagulation fac-
tor deficiency, cryoprecipitate would also be valuable for
factor VIII, von Willebrand factor, and factor XIII replace-
ment, though it is not clear that this was the motivation
behind the selection.
Use of coagulation factor deficient replacement fluids for
TPE proximate to an invasive procedure may increase the
risk for bleeding because of the decrease in coagulation fac-
tors. Thus, some apheresis providers may use plasma or
cryoprecipitate to potentially mitigate this risk. This practice
varies among institutions. For example following kidney
biopsy, 5 of 84 (6.0%) respondents indicate they would use
plasma for up to five or more days after the biopsy, while
13 of 84 (15.5%) of respondents do not routinely use plasma.
With other minor invasive procedures, 25.3% would use
albumin with or without normal saline even if the invasive
procedure is performed in the morning of the TPE. When
the invasive procedure is major surgery, more respondents
would include some coagulation factor replacement, but
8.9% would perform the TPE with albumin with or without
normal saline 1 day after a major surgery. When considering
minor vs major procedures, one limitation of our study was
the different time periods queried between the two scenarios.
Additionally, the data on the use of plasma after a kidney
biopsy may have been clearer to interpret if we had pre-
sented the case patient at multiple days after the biopsy and
inquired what replacement fluid they would use. However,
this would have added several more questions to the end of
an already long survey.
There is very limited data published on the anticoagulant
management in patients undergoing TPE.14–22 As illustrated
in Table 2, replacement fluid containing some or all plasma
or cryoprecipitate would be used by 34.5%-67.1% of respon-
dents with the common anticoagulants unfractionated hepa-
rin, low molecular weight heparin, and warfarin. Several
respondents would use plasma as the replacement fluid
(solely 6.9% or with albumin 35.6%) in a patient who is ther-
apeutic (INR 2.5) on warfarin, a vitamin K antagonist
(VKA). Plasma transfusion can be used as a reversal agent
for VKAs.23–25 The use of all plasma would be expected to
result in significant reversal of the patient's anticoagulation.
Although approximately a quarter of respondents have per-
formed TPE on patients on oral (eg, dabigatran) or
intravenous (eg, lepirudin, argatroban, and bivalidrudin)
direct thrombin inhibitor or an oral direct anti-Xa inhibitor
(eg, rivaroxaban, apixaban, edoxaban, betrixaban), the
impact of TPE on patients on anticoagulants is not entirely
clear. The procedure may remove the anticoagulant medica-
tions as well as the specific anticoagulant targets. There is
limited information on medication removal with TPE, but
several factors influence this including protein binding, vol-
ume of distribution, dose, timing since last dose; volume of
TPE, length of the TPE procedure, successive TPE proce-
dures, and potentially the replacement fluid.8–11 Further
investigation is needed to establish the best practice with
regard to anticoagulants and antiplatelet therapy in the set-
ting of TPE.
There are several other limitations to this study. Because
of the length of the survey, there was a decrease in the num-
ber of respondents throughout the course of the survey. It is
unknown if the practices of the respondents who did not
complete the survey would be different from other respon-
dents. Because of the small numbers, data from respondents
using membrane filtration were excluded from analyses. The
majority of respondents were from the United States of
America. The number of TPE procedures performed by the
respondents is not known as we inquired about total number
of apheresis procedures rather than the specific number of
TPE. An apheresis provider's background, training, and
experiences likely contribute to the choice of replacement
fluid; however, the survey did not capture adequate informa-
tion to analyze these factors.
5 | CONCLUSIONS
The selection of the replacement fluid for TPE depends on
many variables, including the diagnosis for performing the
procedure, concurrent clinical situations, and laboratory
studies. There is little evidence to guide the adjustment of
the replacement fluid content, which likely contributed to
the wide variation in practices seen in this survey. Future
research study is needed to establish best practice.
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